Kornimate/medical-research-clean huggingface dataset:
chloroquine phosphate prophylactic use in health personnel exposed to covid-19 patients

Conditions: COVID-19

Summary: the primary objective of this study is to evaluate the efficacy and security of chloroquine phosphate prophylactic use for reducing the risk of infection by severe acute respiratory syndrome coronavirus-2 in health care workers exposed to covid-19 patients.

health care workers as first line of hospital care, are at high risk of infection by severe acute respiratory syndrome coronavirus-2 due for the exposure to covid-19 patients. the pharmacological treatment with chloroquine phosphate has emerged as one of the main therapeutic approaches for covid-19 patients. however, some studies have described and hypothesized that the use of prophylactic chloroquine phosphate could provide some protection against covid-19 infection reducing the chances of contagion in health care personnel during the development of the pandemic. a controlled clinical trial will be conducted in a tertiary hospital in mexico city, mexico. participants will be divide in two groups; 1) intervention: who will receive chloroquine phosphate (300 mg/day during the first 30 days and 150mg/day during the last 30 days) and 2) control, both with a follow up for 60 days.

Eligibility criteria:
inclusion criteria: * health care workers as first line of hospital care exposed to covid-19 patients. * initial polymerase chain reaction assay negative test for severe acute respiratory syndrome coronavirus-2 infection. * both sexes * agree to participate in the study after signing an informed consent letter. exclusion criteria: * health care workers as first line of hospital care exposed to covid-19 patients with history of heart disease, arrhythmias or qt segment prolongation. * health care workers as first line of hospital care exposed to covid-19 patients with liver or kidney disease of any etiology. * health care workers as first line of hospital care exposed to covid-19 patients with retinopathy of any etiology. * health care workers as first line of hospital care exposed to covid-19 patients with allergy to chloroquine. * health care workers as first line of hospital care exposed to covid-19 patients with a history or diagnosis of psoriasis. * health care workers as first line of hospital care exposed to covid-19 patients with important primary clinical alterations: renal (creatinine\> 3), liver (alanine aminotransferase and aspartate aminotransferase x 3), endocrine, neurological.

Keywords: covid-19 chloroquine phosphate prophylactic health personnel severe acute respiratory syndrome coronavirus-2
study on clinical features, treatment mode and survival of bone and soft tissue tumors

Conditions: Bone and Soft Tissue Tumors; Clinical Features

Summary: it is planned to prospectively collect, collate and report real-world clinical data of bsts patients treated in our hospital in the next ten years to evaluate the changes in clinical characteristics, treatment patterns and survival information of these patients, in order to provide reference for clinical treatment and research of this type of tumor.

it is planned to prospectively collect, collate and report real-world clinical data of bsts patients treated in our hospital in the next ten years to evaluate the changes in clinical characteristics, treatment patterns and survival information of these patients, in order to provide reference for clinical treatment and research of this type of tumor. this study is a single-center, prospective, real-world observational study that plans to enroll all eligible patients. basic information, treatment methods, and prognostic information of these patients were collected.

Eligibility criteria:
inclusion criteria: all ages, male and female. the pathological diagnosis of bsts in our hospital was a subtype. has received at least one hospitalization in this hospital. the target lesions could be evaluated according to the efficacy evaluation criteria of solid tumor (recist; version 1.1) measure diameter changes. exclusion criteria: no definite pathology.
trial of asthma self-management education in patients with depressive symptoms

Conditions: Asthma; Depression; Anxiety

Summary: although depressive and anxious symptoms are common in asthma patients and are associated with worse clinical and resource utilization outcomes, there have been no studies focusing on the particular challenges of improving asthma self-management in this population. the investigators hypothesize that a tailored intervention to improve asthma self-management in patients with a known history of depressive and anxious symptoms will be effective in improving asthma-related quality of life.

depressive and anxious conditions are common during the lifetime of asthma patients and have been shown to be associated with worse asthma as defined by more symptoms, more hospitalizations and greater use of medications. there have been few studies trying to improve asthma outcomes in patients with known depression. one method to improve outcomes is to instruct patients in ways to better self manage asthma. the goal of this study is to test a comprehensive intervention to improve asthma self-management by increasing knowledge and self-efficacy in patients with a known history of a positive screen for depression. patients will be randomized to two groups - a control group and an intervention group. patients in the control group will receive an asthma workbook, will make a contract to adopt behaviors they think will improve asthma, and will receive telephone follow-ups approximately every week for 8 weeks and then approximately every 2 months. patients in the intervention group will receive these components plus they will be taught how to use a peak flow meter and specific chapters of the workbook will be used as templates for focused instruction during telephone follow-ups. the primary outcome will be a comparison of within-patient change in asthma-related quality of life between groups.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * known history of depressive or anxious symptoms exclusion criteria: * pregnant * has cognitive deficits * no access to telephone

Keywords: asthma depression anxiety
examination of biopsies from healthy knee joints

Conditions: Abnormality in Synovial Tissue

Summary: the purpose of the project is to examine what kind of molecular mechanism which causes inflammatory joint diseases. this examination is carried out by a collection and analysis of synovial tissues for patients without inflammatory joint diseases compared to the experienced equivalent biopsies from patients with inflammatory joint diseases.

arthritis is caused by autoimmune disease in the cells and pathogenesis of the tissue. this autoimmune inflammation is very often a chronic disease which causes irreversible articular damage. rheumatoid arthritis is very often a painful and disabling disease if the treatment turns out to be ineffectual. several of the available remedies can not treat the disease totally but only keep the patients in check. the biological mechanisms which cause an autoimmune inflammatory articular disease have not been proved scientifically yet. under normal conditions, the immune system adapts easily in order to protect the body against pathogenic bacteria and virus without causing damage on the body's own cells. autoimmune inflammatory diseases displace this balance in a way so that the immune system can not distinguish between "self" and "non-self". different kinds of cells are involved in this chronic inflammation in the joints. majority of these cells belong to the heart of the immune response, for example t-lymphocytes, b-lymphocytes, macrophages, dendrites and granulocytes. however, other cells are also involved, for example synovial fibroblasts and endothelium. it is very important to understand the interaction of these cells in order to develop new medicinal products for inflammatory articular diseases. the big challenge for conduction research in inflammatory articular diseases is to achieve more evidence-based knowledge of the synovial tissue from the patients and the control group.

Eligibility criteria:
inclusion criteria: * males and females \> 18 years * planned surgery for patients with meniscus or reconstruction of ligament exclusion criteria: * employment at aalborg university hospital * employment at novo nordisk a/s * an unsigned statement of consent * current medical treatment resistant to a course of treatment, for example large doses of steroids

Keywords: rheumatoid arthritis synovial tissue joint destruction inflammation
implementation of physiotherapy on covid-19 patients in icu

Conditions: Sars-CoV2; COVID-19

Summary: despite new charachersitics of covid-19 patients, critical care implementation seems to be similar to those with acute respiratory distress syndrome (ards) in intensive care units (icu). regarding the initial gravity of these patients, sedation and neuromuscular blockers are usually administrated, increasing the risk to develope an icu-acquired weakness which is directly correlated to morbi-mortality and a burden during recovery. respiratory symptoms are mostly related to dyspnoea and non-productive cough, with only 33% of covid-19 patient having a bronchial hypersecretion ; consequently, chest physiotherapy is only implemented in after case-by-case evaluation. this unprecedented situation requires to identify how physiotherapy is being implemented in covid-19 patients in icu. this retrospective, multicentric study aims to identify the charactheristics of physiotherapy (type and time spent) implemented in argentina, belgium, chili, france, italy and spain

* demographics data : hospitalisation date, icu date, covid+ date, extubation date, discharge date, mortality * icu data : ventilatory mode, type of physiotherapy implemented (early rehabilitation, chest physiotherapy, time spent (minutes), number of interventions per day.

Eligibility criteria:
inclusion criteria: * age \> 18 years * patient admitted in icu * patient with covid-19 diagnosis exclusion criteria: - explicite denie to participate in the study

Keywords: covid-19 physiotherapy implementation critical care
a post market study on the use of cormatrix® cangaroo ecm® (extracellular matrix) envelope

Conditions: Cardiovascular Disease

Summary: the objective of the secure study is to actively gather additional information on the use of the cormatrix® cangaroo ecm® envelope in a post market observational study.


Eligibility criteria:
inclusion criteria: * subjects who have received cormatrix® cangaroo ecm® envelope for an implantable electronic device placement. exclusion criteria: -
the change of clinical features and surgical outcomes in patients with pressure injury during the covid-19 pandemic: a retrospective study

Conditions: Pressure Injury; COVID-19

Summary: the covid-19 pandemic has considerably and negatively affected numerous lives and economies worldwide; specifically, it has led to delays in seeking medical treatment among many people \[1-3\]. delaying or avoiding seeking medical advice can result in worsened symptoms, delayed evaluation, and treatment complications \[4-7\]. moreover, the pandemic has significantly impacted health-care systems, leading to numerous issues including shortages of medical staff, beds, equipment, medicines, and isolation facilities. the concern of cross-contamination-where covid-19 may spread within wards unknowingly-has also increased the emotional burden among health-care workers \[8-10\]. pressure injury (pi) is a common health issue particularly among older people who have physical limitations or are bedridden. pi management often requires a long-term individualized plan. failure to implement this strategy may influence the quality of life and may cause wound-related psychosocial issues (e.g., low self-esteem), increase health-care expenditures, and shorten survival among the patients \[11\]. moreover, long-term pis are prone to infection and bleeding, which may lead to sepsis or anemia \[12-14\]. the current study explored whether covid-19 pandemic-related changes affected the characteristics and treatment outcomes of patients with pis.


Eligibility criteria:
inclusion criteria: * all patients who received debridement or flap-reconstruction surgery for pressure injury at wan fang hospital from january 2016 to december 2021. exclusion criteria: * patients who underwent debridement or flap-reconstruction surgery across the pre-covid and covid periods were excluded from the study.
study of advanced bulky malignancies with spatially fractioned radiation therapy

Conditions: Advanced Bulky Malignancies

Summary: expand clinical literature on the use of grid radiation with conventional external beam therapy. vast majority of therapy is for palliative care to provide relief from pain, but has also shown a reduction in the size of tumor mass.

this study will evaluate response to radiation therapy by a large bulky tumor is influenced by adding a single dose of 15 gy grid radiotherapy. to accomplish this, patients with large bulky tumors in the lung, abdomen or pelvis will be randomized to receive either standard palliative radiation or palliative radiation plus a single fraction of grid radiation. tumor response, pain relief and duration of response, and pain control will be monitored. toxicity of treatment will also be followed. the hypothesis of this study is that grid radiation will produce a significant improvement in tumor response and pain control that produces no further increase in acute or late toxicity.

Eligibility criteria:
inclusion criteria: * patients with histologic or cytologic diagnosis of primary or metastatic epithelial cancer or sarcoma located in the head and neck area, lung, abdomen or pelvis. * tumors must have an overall dimension greater than 24 cm2 (bidimensional) with one dimensions \>6 cm, by x-ray, ct/mri scan or clinical exam. * age \>18 * karnofsky \> 70 with life expectancy \>3 months. * patients may not begin new hormone therapy within 2 weeks of initiation of protocol treatment. * no planned initiation of hormone therapy within 2 weeks of protocol therapy * adequate bone marrow function: hb \> 9, white blood cell count (wbc) \> 2,000. hepatic function \< 3x upper limit of laboratory normal values. * laboratory studies will be obtained within 2 weeks prior to randomization. * patients with metastatic sites of disease including brain are eligible provided that life expectancy is \> 3 months. exclusion criteria: * hematologic-related tumors. * tumors overlying critical central nervous system structures including spinal cord, eye or brainstem or require treatment portals over these vital structures. * central nervous system tumors * evidence of other primary malignancy except for carcinoma in situ of cervix or skin cancer excluding melanoma unless disease free for 2 years prior to randomization * patients with spinal cord compression. * prior radiation to treatment field. * concomitant chemotherapy or chemotherapy within past 2 weeks. planned initiation of chemotherapy within 2 weeks of completing protocol treatment

Keywords: large tumors in the head & neck, lung, abdomen or pelvis
clinical trial designed to determine the safety and efficacy of ema401 in patients with painful diabetic neuropathy

Conditions: Diabetic Neuropathies

Summary: the study consists of two periods, the screening period (\~3 weeks) and treatment period (12 weeks). eligibility for the study will be determined by screening tests, physical examination/medical history, and fulfilment of eligibility criteria including assessment of pain completed during the screening period. potential participants will be required to provide written informed consent prior to any study-specific screening procedures being performed. following screening assessments, patients will be randomized to receive either ema401 300 mg bid or placebo. patient study visits during the treatment period are at the end of baseline/randomization visit, and end of weeks 3, 6, 9, and 12, for assessments.


Eligibility criteria:
inclusion criteria: * patients with type i or type ii diabetes mellitus with painful, distal, symmetrical, sensory-motor neuropathy attributed to diabetes, of at least six months duration. * be assessed as suffering from moderate to severe pain across the screening period. the assessment of moderate and severe pain will be made using an algorithm proprietary to spinifex. the investigator/site staff will be informed immediately as to whether the patient is eligible or ineligible on the epro website based on the patient entering all relevant pain scores in the ediary device. * women of child bearing potential (wocbp), must have a negative urine pregnancy test at the screening visit (visit 1) and within 72 hours prior to administration of ip. exclusion criteria: * patients taking any topical treatment for their pdn at the time of screening visit 2 will be excluded, including lidocaine plaster, capsaicin patch, and any other topical preparations of these or any other topical medications (e.g., aspirin, non-steroidal anti-inflammatory drugs (nsaids) for their pdn. * have a blood pressure reading, after resting for at least five minutes, outside a systolic blood pressure range of 84 - 151 mmhg or a diastolic blood pressure \> 95 mmhg. if the blood pressure is outside of the range, a repeat measurement can be taken after the patient has rested. the repeat measurement should be used as the screening value. * have serum aspartate transaminase (ast), or alanine transaminase (alt) levels \> 1.5 x the upper limit of normal or have total bilirubin concentrations \> 1.5 x the upper limit of normal at screening (visit 1). * have hemoglobin a1c \> 11 %. * known history of, or positive laboratory results for hepatitis b virus (hbv), hepatitis c virus (hcv) or human immunodeficiency virus (hiv) infection as defined by being seropositive for hepatitis b surface antigen (hbsag), hcv antibodies or hiv antibodies respectively. * have undergone neurolytic or neurosurgical therapy or use a neurostimulating device for pdn.
"the effectiveness of transvertebral magnetic neuromodulation in patients with detrusor overactivity"

Conditions: Overactive Bladder

Summary: the main hypothesis of this study is that magnetic neuromodulation can be used to correct bladder overactivity. the investigators assume that the transvertebral magnetic stimulation can improve both the subjective state of patients evaluated through questionnaires and objective parameters evaluated through invasive and non-invasive urodynamic studies. this study will compare two protocols for magnetic stimulation of the sacral spine roots (s2-s3 segments). the investigators propose to find out the dependence of the therapeutic effect on the frequency of stimulation, the frequency of procedures and the duration of the treatment course.

the aim of the study is to test the hypothesis that the use of magnetic stimulation of the sacral spine roots (s2 - s3) in patients with idiopathic overactive bladder (oab) will help reduce the clinical and urodynamic manifestations of bladder overactivity.

Eligibility criteria:
inclusion criteria: 1. age \> 18 years; 2. signed informed consent; 3. the presence of oab symptoms: urinary frequency, nocturia, urgency and urge incontinence; 4. the presence of detrusor overactivity patterns based on the results of the urodynamic study (udi) exclusion criteria: 1. the patient, who have been implanted devices that control physiological functions (a pacemaker, a device for deep brain stimulation and chronic epidural brain stimulation, a cochlear implant). 2. convulsive attacks in the anamnesis; 3. taking medications that may trigger the risk of seizures; 4. pregnancy or suspicion on it; 5. the presence in the patient's body of metal elements or objects made with the use of ferromagnets (joint prostheses, eye prostheses, tattoos made using metal ink, surgical clips, staples and other metal suture materials, etc.) 6. chronic cardiovascular and cerebrovascular diseases in the stage of decompensation or recent acute conditions (myocardial infarction, brain stroke, etc.) 7. pelvic organ prolapse (ii-iv stages according to the pop-q system) 8. the presence of urinary tract infection 9. the presence of tumors of the pelvic organs
bicalutamide to block tmprss2 in males with covid-19 infection

Conditions: COVID-19

Summary: covid-19 outcomes are worse in male patients. androgen signaling, therefore, is a target for clinical exploration. tmprss2 is a membrane protease required for covid pathogenesis that is regulated by androgens. blocking tmprss2 with bicalutamide may reduce viral replication and improve the clinical outcome. therefore, the study proposes to test bicalutamide at 150 mg oral daily dosing in a double-blind placebo-controlled randomized trial in male patients with early symptomatic covid-19 disease.


Eligibility criteria:
inclusion criteria: subjects must meet all of the following criteria to be eligible for study participation: * men ≥ 36 years old diagnosed with at least one temperature elevation ≥ 100.4 f., or new cough, or new dyspnea and documented covid-19 positive by approved standard local laboratory assay * men ≥ 18 years but \< 36 years old must exhibit either new cough, or new dyspnea and documented covid-19 positive by approved standard local laboratory assay. * access to working telephone or other form of communication such as email. * randomization within 7 days of covid-positive study result. all subjects will undergo repeat covid-19 assay on day 0 enrollment and a positive test is required to stay on study * written informed consent obtained from the subject and the subject agrees to comply with all study-related procedures exclusion criteria: subjects with any of the following will not be eligible for study participation: * randomization greater than 7 days from a positive covid test result. all subjects will undergo repeat covid-19 assay on day 0 enrollment and a negative test will result in a screen-fail and removal from study * admission to hospital at time of screening * inclusion in another randomized trial for covid therapy * diagnosis of prostate cancer and/or treatment with anti-androgen in the past 3 months * current treatment with any androgen replacement products * prior allergic reaction or intolerance to bicalutamide or other androgen receptor inhibitors * requirement for coumarin product or warfarin products due to potential displacement by bicalutamide * subject unable to take oral bicalutamide * known hepatitis b or c * liver cirrhosis * ast/alt greater than or equal to 3 x institutional uln